Blood pressure must be lowered at a rate appropriate for the patient's clinical condition.• Peripheral edema: The most common side effect is peripheral edema; occurs within 2 to 3 weeks of starting therapy.• Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.• Heart failure: With the exception of amlodipine, calcium channel blockers should be avoided whenever possible in patients with heart failure with reduced ejection fraction (HFrEF). Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Efavirenz: May decrease the serum concentration of Calcium Channel Blockers.Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.Pharmacotherapeutic group: Calcium channel blockers, selective calcium channel blockers with mainly vascular effectsAmlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.


Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. The tablets should be taken with a glass of water independently from meals.

This information has been left on emc for reference purposes.This information is intended for use by health professionalsEach tablet contains 10 mg amlodipine (as amlodipine mesilate monohydrate).The tablets are white to off-white, round biconvex and scored and embossed with “10” on one side.Chronic stable and vasospastic (Prinzmetal's) angina pectoris. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care (see Sections 4.4 and 5.2). Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).
Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. By continuing to browse the site you are agreeing to our policy on the use of cookies. Sumatriptan (Imitrex) was first introduced 20 years ago and a registry of women who took sumatriptan during pregnancy suggests that this is a safe drug. Because of these advant… Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.Children >6 years: Similar to adults on a mg per kg basis; Urine (10% of total dose as unchanged drug, 60% of total dose as metabolites) Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children >6 years of age is similar to adults; Antihypertensive effect: Significant reductions in blood pressure at 24 to 48 hours after first dose; slight increase in heart rate within 10 hours of administration may reflect some vasodilating activity (Donnelly 1993)Antihypertensive effect: At least 24 hours (Donnelly 1993); has been shown to extend to at least 72 hours when discontinued after 6 to 7 weeks of therapy (Biston 1999)Terminal (biphasic): 30 to 50 hours; increased with hepatic dysfunction Hypersensitivity to amlodipine or any component of the formulation.Dosing should start at the lower end of dosing range and be titrated to response due to possible increased incidence of hepatic, renal, or cardiac impairment.